Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia
South San Francisco, CA -- June 8, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with Rituxan ... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 8, 2018 Category: Drugs & Pharmacology Source Type: news
Ibrutinib Plus Venetoclax Shows Promising Activity Against CLL
Bryant FurlowJun 4, 2018In CAPTIVATE, first-line ibrutinib plus venetoclax yielded a high rate of undetectable residual disease, without new safety signals, in chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news
Roche presents new data across a range of blood cancers at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche presented new data from studies in several blood cancers, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML) at the 2018 ASCO Annual Meeting, 1-5 June, in Chicago, IL, United States. (Source: Roche Investor Update)
Source: Roche Investor Update - June 3, 2018 Category: Pharmaceuticals Source Type: news
Phase I trial finds experimental drug safe in treating chronic lymphocytic leukemia
(University of California - San Diego) Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the 'stemness' of chronic leukemia cancer (CLL) cells -- their ability to self-renew and resist terminal differentiation and senescence. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2018 Category: International Medicine & Public Health Source Type: news
CLL patient treated at Penn goes into remission thanks to single CAR T cell
(University of Pennsylvania School of Medicine) Researchers at the University of Pennsylvania's Abramson Cancer Center say a patient treated for chronic lymphocytic leukemia (CLL) in 2013 went into remission because of a single CAR T cell and the cells it produced as it multiplied, and has stayed cancer free in the five years since, with CAR T cells still present in his immune system. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 30, 2018 Category: Cancer & Oncology Source Type: news
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Phase 3 iLLUMINATE trial met primary endpoint of progression-free survival (PFS) in patients with previously untreated CLL and Small Lymphocytic Lymphoma (SLL) compared to chlorambucil plus obinutuzumab as assessed by an Independent Review Committee (IRC)
... Biopharmaceuticals, Oncology AbbVie, IMBRUVICA, ibrutinib, GAZYVA, obinutuzumab, Chronic Lymphocytic Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 24, 2018 Category: Pharmaceuticals Source Type: news
After 6-month wait, cheques land on doorstep of sick Ontario worker
Mitch LaPrade has been fighting the WSIB for 11 years, arguing his chronic lymphocytic leukemia (CLL) was caused by exposure to a carcinogen called benzene. The highest level of Ontario’s workers’ compensation system ruled in his favour last fall, but his cheques only arrived this week after a CBC investigation. (Source: CBC | Health)
Source: CBC | Health - May 11, 2018 Category: Consumer Health News Tags: News/Canada Source Type: news
Lymphoma, Leukemia Survivors Have Increased Health Care Use
WEDNESDAY, May 9, 2018 -- Survivors of lymphoma and chronic lymphocytic leukemia (CLL) have increased use of health care services versus a normative population, according to a study published online April 26 in Cancer.
Lindy P.J. Arts, from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 9, 2018 Category: Pharmaceuticals Source Type: news
Biomarker predicts benefit from immunotherapy
Researchers found a biomarker that, if confirmed, could be used to identify which people with chronic lymphocytic leukemia would benefit from CAR T-cell therapy. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - May 8, 2018 Category: Consumer Health News Source Type: news
T cell biomarker predicts which CLL patients will respond to CAR T cell therapy
(University of Pennsylvania School of Medicine) Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia (CLL) don't respond to chimeric antigen receptor (CAR) T cell therapy, and the answer is tied to how primed patients' immune systems are before the therapy is administered. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 30, 2018 Category: International Medicine & Public Health Source Type: news
Interim MRD May Help Direct Individual Treatment for CLL
Achieving undetectable MRD after chemoimmunotherapy predicted longer progression-free and overall survival in CLL patients. (Source: CancerNetwork)
Source: CancerNetwork - April 27, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Hematologic Malignancies News Source Type: news
Duvelisib Granted Priority Review for R/R CLL/SLL and FL
In the DUO and DYNAMO trials, duvelisib improved clinical responses in patients with R/R CLL/SLL and FL, respectively. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Follicular Lymphoma Hematologic Malignancies News Source Type: news
Venetoclax/Rituximab Found Superior to Chemotherapy in CLL
The combination of rituximab and the BCL2 inhibitor venetoclax significantly lengthened PFS among CLL patients in the phase III MURANO trial. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Hematologic Malignancies News Source Type: news
Efficient control of leukaemia with treatment by dual immune-checkpoint blockade
(Luxembourg Institute of Health) Chronic lymphocytic leukaemia (CLL) is a haematological malignancy. When infiltrating tissues, CLL cells come in contact with healthy cells, including immune cells. Researchers from the Luxembourg Institute of Health (LIH) succeeded in characterising in depth the composition of immune cells and circulating cytokines of the CLL microenvironment in mouse models using mass cytometry. Based on this knowledge, they propose an immunotherapeutic strategy with two immune checkpoint inhibitors that efficiently blocks disease development in preclinical tests. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 17, 2018 Category: Cancer & Oncology Source Type: news
Cancer researchers receive more than $2 million to eradicate common form of leukemia
(Scripps Research Institute) The researchers will investigate how to design antibodies to deliver drugs to fight chronic lymphocytic leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2018 Category: Cancer & Oncology Source Type: news
